Comparative Pharmacology
Head-to-head clinical analysis: TOBRADEX ST versus TOBRASONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOBRADEX ST versus TOBRASONE.
TOBRADEX ST vs TOBRASONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Dexamethasone is a corticosteroid that suppresses inflammation by binding to glucocorticoid receptors, inhibiting phospholipase A2, and reducing prostaglandin and leukotriene synthesis.
Tobrasone is a combination of tobramycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and dexamethasone (a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis).
1 drop into the conjunctival sac of the affected eye(s) every 4 to 6 hours; in severe cases, may be increased to 1 drop every 2 hours. Do not prescribe more than 20 mL per 30 days.
2 mg (as 0.2% topical solution) applied to the affected area twice daily. Not for ophthalmic use.
None Documented
None Documented
Tobramycin: 2-3 hours (prolonged in renal impairment; up to 50-70 hours in anuria); Dexamethasone: 3-4 hours
Terminal elimination half-life is 2.5-3.5 hours in adults, supporting twice-daily dosing for maintenance therapy.
Renal: ~60% as unchanged drug and inactive metabolites; Biliary: ~20%; Fecal: ~20%
Renal elimination of unchanged drug and metabolites accounts for approximately 60-70% of the dose, with biliary/fecal excretion contributing 20-30%.
Category C
Category C
Ophthalmic antibiotic/steroid combination
Ophthalmic antibiotic/steroid combination